A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 23,521 shares of LRMR stock, worth $151,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,521
Previous 23,832 1.3%
Holding current value
$151,710
Previous $172,000 10.47%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$6.3 - $10.68 $1,959 - $3,321
-311 Reduced 1.3%
23,521 $154,000
Q2 2024

Aug 09, 2024

SELL
$6.33 - $9.89 $217,017 - $339,068
-34,284 Reduced 58.99%
23,832 $172,000
Q1 2024

May 09, 2024

BUY
$4.2 - $13.28 $244,087 - $771,780
58,116 New
58,116 $441,000
Q3 2023

Nov 13, 2023

SELL
$3.08 - $4.49 $80,816 - $117,813
-26,239 Reduced 54.58%
21,835 $86,000
Q2 2023

Aug 10, 2023

BUY
$3.13 - $5.27 $19,490 - $32,816
6,227 Added 14.88%
48,074 $150,000
Q1 2023

May 09, 2023

BUY
$4.0 - $6.68 $17,448 - $29,138
4,362 Added 11.64%
41,847 $189,000
Q4 2022

Feb 10, 2023

BUY
$2.73 - $5.08 $66,666 - $124,053
24,420 Added 186.91%
37,485 $154,000
Q3 2022

Nov 10, 2022

BUY
$1.53 - $3.64 $19,989 - $47,556
13,065 New
13,065 $42,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $279M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.